Mission & Vision

At LuminaCare, our mission is to help advance the diagnosis and treatment of patients with infectious disease. Treating patients is difficult.  The factors include variable drug exposures, pathogen identification and potential resistance.  Current technologies can rapidly identify pathogen, but bacterial resistance is a function of multiple bacterial mutations, unknown genes and host factors

We aim to integrate knowledge from infectious disease research, drug discovery, data modeling and software development. We build platforms that enable the physician in their treatment process.  Starting with pneumonia and skin infections, we plan to expand into more areas with relevant collaboration and partnerships.

LuminaCare Solutions offers the first complete product detects drug resistance 600% faster than current methods regardless of resistance mechanism enabling the rapid selection of appropriate tretments in hours vs days.  Accelerating the diagnosis and treatment process improves patient outcomes while reducing costs.   

Our Team

Our strength is our collective, diverse and relevant expertise.  We are biologists, data scientists, software engineers and management professionals with experience in pharmaceutical and health care industries.  Well-versed in data analytics, modeling and simulation of drug exposures and outcomes, clinical infectiouse disease management and cloud-based software development.  

Dr. David Howe, Ph.D.

CO-FOUNDER & CEO

Stephen Chiricosta

CO-FOUNDER & COO

Drug-Resistant Bacterial Infections

In the US, the majority of resistant bactieral infections occur in the hospital setting.  In acute care hospitals, 1 in 7 catheter- and surgery-related hospital acquired infections (HAIs) are caused by drug-resistant bacteria and increases to 1 in 4 in long-term acute care centers.  Treating patients in these settings is difficult.  The factors making treatment difficult include variable drug exposures in these serious ill patients in addition to bacterial resistance is due to multiple bacterial mutations, unknown genes and host factors

LuminaCare Solutions offers the first complete product detects drug resistance 600% faster than current methods regardless of resistance mechanism enabling the rapid selection of appropriate tretments in hours vs days.  Accelerating the diagnosis and treatment process improves patient outcomes while reducing costs.